Showing results (431-440 of 699) with videos related to
Sort By:
Pageof 70
Diabetologia|October 31, 2019
Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 StudyMagnus T Jensen, Peter Sogaard, Ida Gustafsson, et al.Cardiovascular Diabetology|September 16, 2023
Insulin resistance, kidney outcomes and effects of the endothelin receptor antagonist atrasentan in patients with type 2 diabetes and chronic kidney diseaseJ David Smeijer, Donald E Kohan, Peter Rossing, et al.Acta Diabetologica|August 31, 2020
Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarkerSidar Copur, Dimitrie Siriopol, Baris Afsar, et al.ESC Heart Failure|July 29, 2024
Coronary microvascular dysfunction and left heart filling pressures in patients with type 2 diabetesEmil Wolsk, Mikkel Jürgens, Morten Schou, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 14, 2022
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)Jennifer B Green, Amy K Mottl, George Bakris, et al.JACC. Cardiovascular Imaging|March 10, 2015
Global longitudinal strain is not impaired in type 1 diabetes patients without albuminuria: the Thousand & 1 studyMagnus Thorsten Jensen, Peter Sogaard, Henrik Ullits Andersen, et al.Diabetes, Obesity & Metabolism|July 3, 2023
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetesMikkel Jürgens, Morten Schou, Philip Hasbak, et al.Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.American Heart Journal|May 9, 2025
Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trialStefan James, Andreas Dyreborg Christoffersen, Jens-Peter David, et al.Diabetes|July 10, 2021
The Low-Expression Variant of FABP4 Is Associated With Cardiovascular Disease in Type 1 DiabetesEmma H Dahlström, Jani Saksi, Carol Forsblom, et al.Pageof 70